
Redeye Initiates Coverage of Isofol Medical

Redeye re-initiates coverage of Isofol Medical, a Swedish oncology biotech company targeting the multibillion-dollar colorectal cancer treatment market. With a renewed clinical strategy, strengthened financial backing, and strategic support from international partners, we see compelling upside potential as the company works to reestablish arfolitixorin as a next-generation treatment in metastatic colorectal cancer.

Read more and download the Research Report.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Redeye Initiates Coverage of Isofol Medical